Global Ankylosing Spondylitis Industrial and Market studies 2015-2019
"Global
Ankylosing Spondylitis Market 2015-2019"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
About
Ankylosing Spondylitis
Ankylosing
spondylitis is a subtype of spondylarthropathy. The primary symptoms
of the disease are inflammatory spinal pain with subsequent
limitation of spine mobility and chest expansion. Ankylosing
spondylitis can be diagnosed using clinical signs, radiological signs
(sacroiliitis) and the presence of HLA-B27 antigen. According to the
NIH and NIAMS, ankylosing spondylitis is a type of arthritis, which
affects the joints in the vertebral column severely.
It
is a progressive inflammatory disease that typically becomes evident
during early to mid-adulthood, as per NORD. It can also lead to the
loss of spinal mobility for the affected individuals. The cause of
the disease is not known, however, the HLA-B27 gene plays a major
role. Ankylosing spondylitis is hereditary in nature.
TechNavio's
analysts forecast the Global Ankylosing Spondylitis market to grow at
a CAGR of 5.05 percent over the period 2014-2019.
Covered
in this Report
This
report covers the present scenario and the growth prospects of the
Global Ankylosing Spondylitis market for the period 2015-2019. To
calculate the market size, the report considers revenue generated
from the sales of various drugs used in the treatment of ankylosing
spondylitis. The market is segmented based on the mechanism of action
of the drugs used to treat ankylosing spondylitis as illustrated
below:
TNF
Inhibitors
COX
Inhibitors
Others
On
the type of molecule used for the treatment of ankylosing
spondylitis, as illustrated below:
Biologics
Small
Molecules
On
the basis of route of administration adopted for the treatment of
ankylosing spondylitis, the Global Ankylosing Spondylitis market is
segmented as follows:
Oral
Parenteral
In
addition, the market is also bifurcated on the basis of dosage forms
of the drugs used in the treatment of the disease:
Solid
Liquid
The
report also presents the vendor landscape and a corresponding
detailed analysis of the top five vendors in the market. The vendor
landscape section includes a market share analysis of the major
vendors along with the competitive performances of their product
portfolios. In addition, it discusses the major drivers that
influence the growth of the market and also outlines the challenges
faced by the vendors and the market at large, as well as the key
trends that are emerging in the market. Also, the late-stage pipeline
molecules developed for the treatment of Ankylosing Spondylitis have
been discussed.
Global
Ankylosing Spondylitis Market 2015-2019, has been prepared based on
an in-depth market analysis with inputs from industry experts. The
report covers the Americas, the APAC region and the EMEA; it also
covers the Global Ankylosing Spondylitis market landscape and its
growth prospects in the coming years. The report also includes a
discussion on the key vendors operating in this market.
Key
Regions
Americas
APAC
EMEA
Key
Vendors
Abbvie
Amgen
Janssen
Pharmaceuticals
Merck
& Co.
Pfizer
Other
Prominent Vendors
Boehringer
Ingelheim
Bristol-Myers
Squibb
Celgene
Celltrion
Eisai
F.
Hoffmann-La Roche
Merck
Sharp & Dohme
Novartis
Otsuka
Pharmaceutical
Regeneron
Pharmaceuticals
Sanofi
Shanghai
Pharmaceuticals
UCB
Market
Driver
Presence
of Unmet Need
For
a full, detailed list, view our report
Market
Challenge
Threat
from Patent Expiry
For
a full, detailed list, view our report
Market
Trend
Market
Dominance by Biologics
For
a full, detailed list, view our report
Key
Questions Answered in this Report
What
will the market size be in 2019 and what will the growth rate be?
What
are the key market trends?
What
is driving this market?
What
are the challenges to market growth?
Who
are the key vendors in this market space?
What
are the market opportunities and threats faced by the key vendors?
Comments
Post a Comment